Lumevoq: Withdrawal of the marketing authorisation application

lenadogene nolparvovec


Gensight Biologics SA withdrew its application for a marketing authorisation of Lumevoq for treating loss of vision due to an eye condition known as Leber hereditary optic neuropathy.

The company withdrew the application on 20 April 2023.

  • List item

    Questions and answers on the withdrawal of application for the marketing authorisation of Lumevoq (lenadogene nolparvovec) (PDF/136.98 KB)

    First published: 26/04/2023

  • Key facts

    Product number
    International non-proprietary name (INN) or common name
    • lenadogene nolparvovec
    Active substance
    • lenadogene nolparvovec
    Date of withdrawal
    Company making the application
    GenSight Biologics S.A.
    Withdrawal type
    Initial authorisation

    All documents

    Related content

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating